Eli Lilly has partnered with Chinese digital healthcare platform JD Health International to sell its GLP-1s to patients online, Bloomberg reported Aug. 29.
The collaboration will offer a streamlined, one-stop service through JD Health, including online consultations, prescriptions, drug delivery and follow-up care, according to a statement posted on Eli Lilly’s WeChat account. The drugmaker currently markets Mounjaro for both obesity and diabetes in China.
China’s state medical insurance previously said it wouldn’t cover drugs for weight loss purposes, prompting more drugmakers to prioritize online drug channels.
Eli Lilly’s rival Novo Nordisk has also partnered with major platforms, including JD Health, Tencent Health, Ping An Healthcare and Alibaba Health.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.